J. Stern & Co. LLP Has $3.03 Billion Stake in Zoetis Inc. $ZTS

J. Stern & Co. LLP lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 12,431.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 24,069,492 shares of the company’s stock after buying an additional 23,877,416 shares during the period. Zoetis makes up 0.9% of J. Stern & Co. LLP’s investment portfolio, making the stock its 23rd biggest position. J. Stern & Co. LLP owned approximately 0.06% of Zoetis worth $3,028,423,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of Zoetis by 12.9% during the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after purchasing an additional 5,474,210 shares in the last quarter. State Street Corp grew its holdings in shares of Zoetis by 0.8% during the 4th quarter. State Street Corp now owns 19,796,891 shares of the company’s stock worth $2,490,845,000 after purchasing an additional 149,382 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Zoetis by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock worth $1,420,294,000 after purchasing an additional 189,235 shares in the last quarter. Norges Bank acquired a new stake in shares of Zoetis during the 4th quarter worth $734,425,000. Finally, Deutsche Bank AG grew its holdings in shares of Zoetis by 19.1% during the 4th quarter. Deutsche Bank AG now owns 5,558,183 shares of the company’s stock worth $699,331,000 after purchasing an additional 891,921 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Frank A. Damelio bought 6,650 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The shares were acquired at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the acquisition, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. This represents a 44.91% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Michael B. Mccallister purchased 3,000 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were acquired at an average price of $77.76 per share, with a total value of $233,280.00. Following the completion of the acquisition, the director owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders bought 11,650 shares of company stock worth $886,384. 0.22% of the stock is currently owned by insiders.

Zoetis Stock Performance

Shares of ZTS stock opened at $79.28 on Wednesday. The business’s 50-day moving average price is $95.41 and its 200-day moving average price is $113.49. Zoetis Inc. has a 12 month low of $72.38 and a 12 month high of $164.32. The firm has a market capitalization of $33.24 billion, a price-to-earnings ratio of 13.15, a PEG ratio of 1.25 and a beta of 0.75. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same period in the previous year, the business posted $1.48 earnings per share. The business’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities research analysts forecast that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is currently 35.16%.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Negative Sentiment: The flood of class-action reminders highlights alleged investor harm and creates another headline risk for Zoetis, which can weigh on sentiment while litigation moves forward. Article Title
• Negative Sentiment: Several law firms allege securities-law violations tied to the same class period, reinforcing uncertainty around prior disclosures and potentially keeping pressure on the stock. Article Title
• Neutral Sentiment: The company’s recent earnings backdrop remains a separate concern: Zoetis previously missed both EPS and revenue estimates, which may continue to influence investor caution.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Leerink Partners restated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Argus reaffirmed a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. UBS Group reduced their price objective on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a research note on Friday, May 8th. William Blair reaffirmed an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Finally, Citigroup reduced their price objective on Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Six research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $133.92.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.